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Decision aids (DAs) are interventions designed to help people make
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There is an ongoing discussion about the quality of DAs. The present
article provides an overview on systematic approaches using various
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SinceDAsaremulti-componentinterventions,single-outcometrialsare
not sufficient for complete quality assessment. Consideration of theor-
etical founding and the development process is required. In an earlier
paper we proposed a novel concept of quality to meet this challenge.
We introduced MATRIX a guide for quality assessment of DAs aimed at
disclosing the rationale behind underpinning theories, methods, and
goals of a DA.
The present paper reports how the development of MATRIX progressed
including results of pre-testing and a feasibility study. We present the
revised version of MATRIX, explain its basic concept, and describe the
way to use it.
Keywords:decisionaids,decisionsupporttechniques,methods,health
care evaluation mechanisms, patient information, evidence based
medicine
Zusammenfassung
Entscheidungshilfen (Decision Aids, DAs) werden entwickelt, um Men-
schen zu unterstützen, gesundheits- bzw. krankheitsspezifische abwä-
gende Entscheidungen zu treffen, indem die relevanten Informationen
über die Entscheidungsoptionen und Outcomes bereitgestellt werden.
DieBeurteilungderQualitätvonDAsistGegenstandwissenschaftlicher
Diskussionen. Die vorliegende Arbeit bietet einen Überblick über ver-
schiedene systematische Ansätze der Qualitätsbeurteilung. Indes hat
sichkeinerdieserAnsätzebislangdurchgesetzt.DieQualitätsbeurteilung
vonDAsbeschränktsichaufWirksamkeitsnachweiseüberkontrollierte
StudienanhandeinzelnerErgebnisparameter.DaDAsjedochkomplexe
Interventionen sind, die aus multiplen Komponenten bestehen, kann
deren Qualität mit diesem Vorgehen nicht vollständig beurteilt werden.
TheoretischeFundierungundEntwicklungsprozessmüssenBerücksich-
tigungfinden.IneinerfrüherenArbeithabenwireinneuartigesKonzept
vorgeschlagen,dasdiesenAnforderungenentsprechensoll.Wirstellten
MATRIX vor, eine systematische Anleitung zur Evaluation von DAs, die
daraufzieltdenZusammenhangzwischenTheoriebasierung,Methoden
und Zielen des DAs offen zu legen.
Mit der vorliegenden Arbeit berichten wir über Fortschritte bei der Ent-
wicklungvonMATRIX,einschließlichPre-TestundMachbarkeitsstudien.
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Grundkonzept und beschreiben, wie das Instrument verwendet wird.
Introduction
Decision aids (DAs) are interventions designed to help
people making specific and deliberative choices among
options by providing information about the options and
outcomesthatisrelevanttoaperson'shealthstatus[31].
Detailed definitions of DAs have been published by the
CochraneCollaboration[31]andtheInternationalPatient
Decision Aid Standards (IPDAS) Collaboration [15]. DAs
addressavarietyofhealthdecisions[30],e.g.onprevent-
ativemeasures,ondiagnosticproceduresorontreatment
options. DAs appear in various forms, e.g. decision
boards, booklets, interactive software and videos. They
aim to achieve various goals, e.g. to enhance knowledge
and to strengthen patient autonomy.
Finally, decisions are made even without a DA. So, what
does a DA contribute? DAs are expected to improve the
quality of decisions by strengthening patients' autonomy
and comprehension [15], [31]. Following the concepts of
shared decision making and informed choice a “good
decision” is characterised by the extent to which it is in-
formed and in consent with patients' personal values
[10], [27], [31], [33]. DAs aim to enhance knowledge, to
generate realistic expectations and satisfaction with the
decisions, and to reduce decisional conflict [29].
However, since efficacy studies on DAs do not provide
sufficient evidence, further research is needed [1], [27],
[31].
In an earlier paper we systematically reviewed current
methods of development and quality assessment of DAs
[16]. We identified a number of systematic approaches
[1], [2], [4], [5], [6], [10], [14], [17] covering important
quality criteria. However, the approaches are not yet im-
plemented.
Thecurrentscientificdiscussionaboutqualityassessment
of DAs addresses four central issues.
1.) Since DAs are complex interventions, studies using
single-outcome measures alone are not sufficient for
quality assessment [28], [16], [23]. The U. K. Medical
ResearchCouncil(UKMRC)proposesaphasedevaluation
approach including both qualitative and quantitative
methods [12]. Beyond efficacy and effectiveness the
modelling of the intervention and the underlying theory
are to be analysed [3], [12].
2.) Goal setting deserves closer attention [3], [4], [29]. It
iscriticisedthattherationaleforparticulargoalstargeted
by a DA as well as the evaluation concepts are not iden-
tifiableintherelatedbackgroundliterature[4],[16].Since
“goalsettingdrives measurement”[4] outcomeparame-
tersforefficacyproofhavetobepreciselyoperationalised.
3.) It is challenged that commonly used outcome para-
meters are appropriate surrogates for informed choice
[2], [17]. Thus, the validity of available efficacy proofs is
questionable [2], [17].
4.) Although several DAs achieve desirable effects, it is
not yet clear, why. It is hardly possible to interpret results
from controlled efficacy trials without being able to draw
conclusionsaboutthemediatingmechanisms.Developers
of DAs ought to make transparent and explicit their ana-
lytical reasoning for making predictions about how DAs
can be expected to achieve their goals [1], [4], [16], [27].
Consequently, a concept of quality should focus the me-
diating mechanisms between goals and methods.
The present article gives an overview on current quality
assessment of DAs. Based on a critical appraisal of
identifiedevaluationsystemsweintroduceanewconcept
of quality. Results of pre-testing and of a feasibility trial
of this novel assessment guide are reported.
Qualityassessmentofdecisionaids
Three evaluation systems were identified, designed to
structure the issue of DA quality implying both, guidance
for development processes and criteria for quality ap-
praisement.
The ‘CREDIBLE’-criteria
The Ottawa Health Research Institute (OHRI) provided
‘CREDIBLE’, a checklist for quality assessment of DAs
(Table1)[31].TheevaluationguidewasusedbytheOHRI
as a standardized reporting format to communicate the
quality of DAs [31], until the OHRI recently switched to
the IPDAS criteria. The CREDIBLE-criteria were used for
thequalityassessmentofDAswithintheCochranereview
[31].
Table 1: The ‘C.R.E.D.I.B.L.E.’ criteria
The IPDAS criteria
Aiming to establish international standards for develop-
ment and evaluation of DAs the IPDAS collaboration in-
tendsto achieve a consensuson a set of minimalcriteria
for quality assessment [13]. Beyond an appraisal of ef-
fectiveness further evaluation criteria are included, e.g.
characteristicsofthedevelopmentprocessandmethods
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ia, proposedby the IPDAS collaboration[7] resulted from
abroadvalidationprocedure,initiallybasedontheadop-
tionofthe‘CREDIBLE’-items.Thesewerecompletedand
met in an international voting on the importance of each
criterion. By this procedure the collection of relevant cri-
teria became more comprehensive. The resulting guide
contains 80 criteria in 12 quality domains (Table 2). Fur-
thermore,theIPDAScollaborationpublishedanexhaust-
ive collection of evidence on their quality aspects [14].
Each quality aspect is theoretically explained and re-
viewed by a group of experts.
Table 2: IPDAS - Categories of quality items
‘CREDIBLE’ and IPDAS criteria are item checklists. They
cover important aspects of quality in some particular
contexts but the underlying concept of quality is not ex-
plained.WhichcriteriaareessentialforahighqualityDA?
Doescomprehensiveperformanceinall80itemsstrongly
indicate high quality? The IPDAS criteria guide a reviewer
to investigate and to describe the DA in detail but they
do not provide instructions how to proceed if criteria are
more ore less important for the critical appraisal of a
particular DA.
The Ottawa workbook
The ‘Workbook on Developing and Evaluating Patient
Decision Aids’ (in the following workbook) published by
O’Connor and Jacobsen is a detailed and systematic
manual to develop and evaluate DAs (Table 3) [29].
Table 3: The Ottawa workbook – seven steps of development
and evaluation of decision aids
Thefirstsequence(steps1,2and3)guidesthedeveloper
as well as the reviewer to analyse the decision context,
e.g. the specific difficulties of the decision making, the
needs of the target group or the availability of evidence.
Thegoalshavetobeclear,specific,andmeasurable.The
guidance includes the consideration, that the goals de-
termine the outcome parameters of the efficacy trial.
The second sequence of evaluation (steps 4 and 5) at-
tends to the selection of the specific decision support
methods referring to the goals of the DA. In step 4 the
developer and the reviewer, respectively, are recommen-
ded to consider a decision support framework as a suit-
able theoretical background to deduce the methods of
the DA. Examples of frameworks are suggested: the
concept of ‘Shared Decision Making’ [5]; the concept of
‘Evidence Based Patient Choice’ [8], [9]; the ‘Motivation
Theory’and‘TheoryofReasonedAction’[32];the‘Ottawa
Decision Support Framework’ (ODSF) [29]. A concrete
procedure how to use a decision support framework to
arrive at the methods is not outlined.
The ODSF is described in detail in the workbook. It pro-
poses ascertained strategies to solve three defined cat-
egories of decisional problems. E.g. unrealistic expecta-
tions (perceived probabilities of outcomes) may be re-
aligned by presenting probabilities of outcomes that are
tailored to the patient’s clinical risk and by describing
outcomes that they are easy to imagine and identify with
[29].
Step 5 provides an overview of common contents and
methods of DAs. Concrete strategies are exemplarily de-
scribed, e.g. to present contents and probabilities of
outcomes, methods of value clarification, coaching and
communicationindecisionmaking,methodsofdelivering
DAs and preparing practitioners. The developer of a DA
gets access to the wide practical experience of the OHRI,
but the theoretical founding of the methods described
remains unclear.
Within the third sequence (steps 6 and 7) procedures to
developandmethodstoevaluateaDAarerecommended.
Theauthorsoftheworkbookemphasisethatdevelopment
and evaluation depend on the objectives of DAs. De-
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chitecture, the criteria for evaluation and the measure-
menttoolsthatwillbeusedtooperationalisethecriteria.
In contrast to the checklist approach of ‘CREDIBLE’ and
theIPDAScriteriathe workbookfocusesthedevelopment
procedure.Withthe workbookanotherconceptofquality
wasintroduced.Itallowsappraisalofavarietyofformats
of DAs. Furthermore,it provides a structurefor the evalu-
ation procedure comparable to the framework of the
UKMRC [12], considering that DAs are complex interven-
tions.
However, it is not explained how to use a theoretical
framework for decision support when deciding on meth-
ods and mediating mechanisms.
Introduction of a new evaluation
guide
InanearlierpaperweintroducedMATRIXasafirstversion
of a new guide for evaluation of DAs [16], based on the
workbook of O’Connor and Jacobsen [29]. The sequence
of selecting methods proposed in the workbook was re-
structured, and the UKMRC approach of evaluation of
complex interventions [12] was implemented. With the
new approach we aimed at supporting the reviewer to
retrace the methodological decisions made by the de-
veloper.Areflectionmatrixwasdevelopedtosupportthis
reviewing process by correlating the goals of a DA with
decisions made on effect mediators. Effect mediators
are design features (e.g. the contents, the setting, the
presentationform,andthemedia)mediatingtheintended
effects of the DA [16].
The reflection matrix was embedded into a systematic
evaluationguide,designedtosupportthereviewerexplor-
ing the rationale of goals and methods and critically ap-
praising the evidence on efficacy and on effectiveness
of a DA.
We already discussed the underpinning theory and de-
scribed the modelling of its components [16]. In the fol-
lowing we report how the development of MATRIX pro-
gressed, finally leading to an evaluation guide. MATRIX
is primarily designed to support quality appraisal, which
is emphasised in the present evaluation trials. However,
sincequalityappraisalanddevelopmentarecloselyinter-
relatedintheMATRIXconcept,itisintendedforguidance
of structured development of DAs as well.
Develoment of MATRIX
The current version of MATRIX is based on a five steps
evaluation procedure (Table 4), which is also reported in
the following. The first version of MATRIX underwent pre-
testing (September to October 2004) and two feasibility
studies (May to July 2005 and March to September
2006). The CREDIBLE guide was chosen as reference
standard.
Table 4: Development procedure of MATRIX
1. Pre-testing and first revision of
MATRIX
In the first study (pre-testing), two Ottawa DAs [19] were
quality assessed by four external experts in the field of
shared decision making. The first version of MATRIX [16]
and CREDIBLE were used as evaluation guides. Back-
ground publications of the DAs were provided [18], [24],
[25], that had been identified in systematic database
searches[22].Topreventordereffects,twoexpertswere
instructed to use the MATRIX version first and then the
CREDIBLE-Criteria, two were instructed in the opposite
order. In-depth interviews were conducted analysing the
feasibility and differences in the evaluation procedures.
Following the experts’ comments MATRIX underwent a
revision focused on reduction of complexity and textual
simplification.
2. First feasibility trial and second
revision of MATRIX
One Ottawa DA [19] was quality assessed by 15 experts
in the field of shared decision making using the revised
version of MATRIX and CREDIBLE. The objective of this
study was to investigate whether MATRIX is understand-
able and feasible. The guide used in the study was in
German language. The participating experts were re-
cruitedbypersonaltelephonecontacttoGermanexperts
associated with research in the field of shared decision
making, scientists, consultants and policymakers. Inclu-
sion criteria were English language competence, know-
ledge about DAs, ability to respond in a given two week’s
period.Noparticipantswererecruitedoutoftheauthors’
research group. The background publication [18] of the
OttawaDAwasprovidedforassessment.Topreventorder
effects the order to use the evaluation guides was ran-
domised. Characteristics of the evaluation procedure
were surveyed by a 13-item questionnaire, which the ex-
pertswereaskedtocompleteafterreviewingtheDA.The
first 7 items addressed the “comprehensibility” and
“feasibility”oftheguides.Furthermore,inordertoinform
the interpretation of these feasibility ratings, a set of 6
items was added to the questionnaire. The participants
were asked to express their attitudes towards underpin-
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generated by use of each evaluation guide. Answering
format of the questionnaire was a four point Likert-scale
combined with an open answering space (Table 5). Parti-
cipants were asked to rate their agreement to a given
statement ranging from ‘very’ to ‘not at all’. Mean differ-
ences between the ratings lower than 0.3 were regarded
as equal.
Table 5: Answering format of the questionnaire items
Out of 15 experts 14 completed the questionnaire. The
participants’ expertise in DA-development was rated on
a four point scale between 1 = newcomer to 4 = de-
veloper.Theexpertisescoredby2.5inmean(mean=2.5,
SD=1)inthemiddleofthescale.Thequantitativeresults
are presented in Table 6.
In this study, CREDIBLE was rated higher compared to
MATRIX guide concerning “comprehension of the con-
tents”,“answerabilityofthequestions”and“effortbenefit
relation”. Many comments were made regarding the
“answerability of the questions” and the “availability of
background information” on the DA. Some found fault
withMATRIXastheywerenotabletoidentifytherequired
information. Others commented this phenomenon by
mentioningMATRIXwould“uncoveralackofbackground
information in the literature” (n=6). Some participants
(n=6) mentioned “the higher effort of MATRIX was ad-
equate regarding its advantages”.
No differences in mean values were found in “structural
comprehension”, “clarity of the basic concept of DA
quality” and “utility of the systematic approach”. Never-
theless, polarised statements were found, representing
the controversial discussion on these issues. Some ex-
perts (n=6) complain “difficulties to apply the reflection
matrix” (Section B of MATRIX). Other comments (n=5)
referred to CREDIBLE, as its implicit structure was per-
ceived as neither traceable nor exhaustive.
In sum, the MATRIX approach was expected to result in
more“systematic”and“complete”reviewsandtoimprove
”accuracy”, “transparency” and “validity” of the reviews.
A part group appreciated the new quality concept men-
tioning its accuracy and exhaustive approach. One parti-
cipant expected MATRIX to “stimulate development of
highly adaptive DAs in an evolutionary sense”.
To address remaining difficulties in comprehension of
the terminology, the underpinning quality concept, the
MATRIX guide was revised in terms of simplification.
3. Second feasibility trial
To retest the revised version of the MATRIX guide a
second feasibility trial was undertaken. Again, compre-
hension and feasibility were objects of research. 24 sci-
entists and health care stake holders from Germany, the
Netherlands and the UK were asked for participation. Fi-
nally 15 participants - 10 of them already participants in
the previous trial - completed the task. One Ottawa DA
[21] had to be appraised supported by MATRIX and the
CREDIBLE guide, which both were provided in English
language. The MATRIX translation had been revised by a
native speaking scientist and validated by retranslation.
The application sequence of the evaluation guides was
randomised. Background publications [11], [20] of the
Ottawa DA were provided for appraisement, which had
previously been identified in systematic database
searches [22]. To evaluate the appraisal procedures the
same questionnaire as in the first trial was used. The
questionnaire was provided online. The participants’ ex-
pertisewasassessed.Twoofthemdescribedthemselves
as developers, six as newcomers in the field. Since our
study particularly focused the evaluation processes
guidedbyCREDIBLEandMATRIX,thereviewsthemselves
or the assessments` results concerning the evaluated
DAs were not collected.
The pattern of results (Table 7) was similar to the first
feasibility trial. The comments revealed two main diffi-
culties when using the MATRIX guide: firstly, that inform-
ation defined as essential for evaluating the DA was not
available; secondly, to understand and use the reflection
matrix (Section B of MATRIX). The latter was commented
e.g.: “Why does MATRIX not consider basic criteria as
‘conflict of interest’ or ‘update’”. However, the reflection
matrix is designed to appraise such criteria.
The subgroup analysis of the 10 reviewers participating
in both studies shows that revision of MATRIX did not
change“comprehension”and“feasibility”.Focussingthe
attitudesofthe10reviewersashifttodisagreementwith
the MATRIX concept becomes apparent. In particular,
they sceptically commented the impact of MATRIX on
“accuracy”and“traceability”ofthereviews.Theattitudes
towards the validity of the quality concept remained un-
changed compared to CREDIBLE.
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Quality assessment using MATRIX
In the following we presentthe currentversionof MATRIX
as it was revised after the first feasibility study and re-
tested in the second study. The evaluation procedure
with MATRIX follows three steps (A, B, and C) of system-
atic appraisal (Figure 1). MATRIX supports the reviewer
to collect and appraise information relevant for quality
judgement comprehensively. However, the guide does
notprovideaninstructionforthereviewerhowtoproceed
when weighting and integrating the appraisals to come
to a judgement. An example for the use of MATRIX to re-
view a decision aid is provided in Attachment 1.
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The quality of a DA is limited by the appropriateness of
its goals. They are appropriate, if there is a rationale to
see them as important in a particular decision making
context. Usually, important outcome measures are the
operationalised goals [4].
The goals should be defined in terms of measurable di-
mensions. For example: if the goal is empowerment,
measurable dimensions can be social- and self-compe-
tence,knowledge,andsenseofresponsibility.Thisallows
operationalisation into one or more outcome measures
[4]. If the goal is to support “informed choice” in terms
of the approach of Marteau et al., a multidimensional
outcome measure can be used [26]. This measure com-
prisesaneight-itemscaleofknowledge,afour-itemscale
assessing attitudes towards undergoing the screening
test and a record of test uptake.
To identify the goals of the DA, publications referring to
theunderlyingtheory,modellingoftheDAandexploratory
trials are to be considered.
B. Appropriateness of effect mediators
- the use of the reflection matrix
The reflection matrix unfolds between the goals of a DA
and categories of effect mediators (contents, structure,
complexity, setting, presentation form, and used media).
The rationale underlying the relation between goals and
effectmediatorsshouldbeappraisedcritically,byreflect-
ing on the mechanisms by which a developer expects to
achieve the goals. It should be proved whether these
mechanisms are explained and whether they are trace-
able and supported empirically.
Theeffectmediatorsshouldbeassessedconsideringthe
founding theory, plausibility (e.g. time-frame, target
group),andethicalstandardsandpre-studiesconducted
by the developers in the target group. Practically, the re-
viewer is guided from cell to cell of the reflection matrix
to assess, whether the decisions to use certain effect
mediators are justified (Figure 1). Within each cell,
questions can be framed to explore the mechanisms by
which the effect mediators are expected to achieve the
goals. Three examples: 1) “In considerationof the partic-
ulargoal,istheusedpresentationformjustifiedbytheory
or by evidence out of studies or by ethical considera-
tions?” 2) “In consideration of the particular goal, is the
degree of complexity of the DA justified by theory or by
evidence out of studies or by ethical considerations?”
3) “In consideration of the particular goal, is the used
medium justified by theory or by evidence out of studies
or by ethical considerations?”. The comprehensive ana-
lysis of the goal-methods interrelation which is represen-
ted in the full matrix provides the basis for the reviewer’s
judgement.
C. Efficacy and effectiveness
The DA is effective if the goals defined by the authors of
the DA have been achieved. Therefore, randomised con-
trolled trials and implementation trials needed to be
conducted [12]. The reviewer should critically appraise
studies on efficacy, effectiveness and implementation.
In particular, it should be proved, whether the outcome
measures used in the trials are patient relevant and
whether they represent the particular goals of the DA,
whether the dimensions of goals were operationalised
appropriately (e.g. if the goal is empowerment, measur-
able dimensions may be social- and self-competence,
knowledge,andsenseofresponsibility),andwhetherthe
data on effectiveness support the intended mediating
mechanisms.
Discussion
Quality assessment of DAs is a challenging endeavour.
DAs address a variety of health decisions, appear in
various forms, and aim to achieve various goals. Quality
assessment needs to consider the specificity of DA con-
cepts. The CREDIBLE guide [31] is easy to use, but does
not consider all important quality criteria. The IPDAS-
evaluation criteria [7] and the Ottawa workbook [29] in-
cludeimportantqualitycriteriaforDAsbutdonotprovide
a transparent step by step strategy to systematically
analyse the mediating mechanisms intended by the
methods of a DA.
The use of DAs is expanding. New concepts of DAs have
been developed and various approaches of decision
supportareconceivable.Toincludepotentialapproaches,
a concept of quality needs to go beyond the scope of
status quo. MATRIX meets this challenge by focusing the
traceabilityofthedevelopmentprocessandtheinherent
rationale of the DA. In this respect, high quality means,
that the mediating principle between goals and methods
is justified by evidence, theory or plausibility.
Based on the MATRIX approach, a guide for reviewers
has been developed to analyse the effectiveness of DAs
in terms of complex interventions. That requires access
to information about the development process [3], [12],
[16], [22], [23].
ResultsofthefeasibilitytrialsshowthattheMATRIXguide
was predominantly rated to be more complicated. The
comments, given by the participants were insightful to
understandtheproblemsofMATRIX.Firstly,someimport-
ant quality aspects could not be assessed, because of
unavailable background information. That might be un-
satisfyingforareviewer.However,unavailabilityofinform-
ation can be due to limited search strategies or due to
unpublished data. Secondly, some quality criteria of
MATRIX were perceived to be too abstract, e.g. “does an
explicit rationale for the selection of the goals exist?” In
particular, if a rationale is not identifiable, it might be
difficult for the reviewer to get an idea what a good per-
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for more guidance and explanation in the MATRIX guide.
Thirdly, by focusing the development process of the DA,
MATRIX seems to interfere with intuitive evaluation
strategies,whichprimarilytendtofocusthefinalproduct
(the DA). This can cause cognitive dissonance: e.g. a DA
canappearonhighstandard;however,withoutsufficient
background information the DA would be critically ap-
praised as insufficient due to lacking traceability.
Unfortunately, it is at present not readily possible to
identifythebackgroundinformationofcurrentlyavailable
DAs with commonly used database search strategies
[22]. The MATRIX approach emphasizes once more that
systematic access to such information is necessary.
MATRIX may also facilitate methodological research,
representing a framework for existing and non-existing
evidence: if frequently targeted goals (e.g.: information,
value clarification, participation [29]) and categories of
effect mediators (e.g. setting, content, presentation, and
media)areinsertedintothereflectionmatrix,theexisting
evidence could be arranged within the cells and gaps of
research become apparent. E.g. while within the cell “in-
formationXpresentation”comprehensiveevidencemight
exist, the cell “value clarification X media” might appear
empty. An empty cell indicates the need for research on
this particular issue.
MATRIXisstillunderdevelopmentandevaluation.Itexists
in a print version. We plan to develop an interactive soft-
ware version, which is expected to be more suitable to
unfold the reflection MATRIX. The evaluation guide then
has to pass further feasibility testing. Outcome parame-
ters need to be determined for a randomised controlled
trial, to generate evidence whether MATRIX influences
traceabilityandvalidityofthereviews,andinter-reviewers’
reliability.
The use of MATRIX requires an intensified attention and
more time than a check of standard criteria. This effort
has to be valued with regard to the state of research on
DA quality. If evidence indicated an existing high quality
standard of current DAs in general, there would be no
need for implementation of a more systematic concept.
However, at the moment we do not know enough about
theefficiencyofmethodstosupportlaypeople’smedical
decision making.
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